Rare Variant and Epigenomic Analysis in ME/CFS
Duration: 36 months, Funding volume: € 999,169
Predicting the evolution of relapse in Wilms tumour using drug sensitivity profiling and liquid biopsies
Funding volume: € 999,538
Personalized risk assessment for embryonal tumor predisposition
Funding volume: € 999,003
Mechanism-based Reversibility Evaluation and Stratified Endophenotyping of Treatment-response in ME/CFS
Duration: 36 months, Funding volume: € 999,930
Waveform Adaptation, Visualization, Export & Standardization framework: Toolkit for Analytics & Reuse
Duration: 12 months, Funding volume: € 84,980
Decoding GNB1E: Advanced Drug Repurposing for Personalized Treatment
Duration: 48 months, Funding volume: € 999,979